ARTV

Artiva BiotherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$7.62

+10.9% vs current

Most likely

Base case

55%

Probability

Target price

$4.76

-30.7% vs current

B-

Bear case

25%

Probability

Target price

$2.54

-63.0% vs current

AI sentiment snapshot

Latest data as of 2025-11-21

AI commentary

Market tone is cautious-to-bearish with heightened focus on near-term data and cash runway; recent price action shows pressure and elevated volume on down days [#News-2025-11-20]. Analyst discourse centers on binary clinical outcomes and dilution risk rather than broad optimism [#AnalystNotes].

RankAlpha Sentiment AI - 2025-11-21

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

-catalystPartnership or acquisition interestHigh impact

Strategic collaboration or M&A by a larger immuno-oncology player could re-rate shares if announced; probability limited but payoff high [#IR-press].

2026-03-31eventClinical data readouts for NK cell therapy candidatesHigh impact

Upcoming or recent clinical data readouts from Artiva's allogeneic NK programs could drive large binary moves if efficacy/safety materially surprise [#10-Qp31], [#PR-2025-08-14].

2026-06-30catalystCash runway / financing needHigh impact

Biotech firms at this stage often require equity raises; a dilutive financing announcement would likely pressure the share price [#10-Qp12].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-11-21 • Updated nightlySource: Internal modelMethodology